Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome

#840

Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).

Aim(s): To evaluate the effect of cumulative dose (CD) on survival in patients (pts) treated with everolimus for advanced pNETs.

Materials and methods: Twelve pts with advanced pNETs were treated with everolimus. Pts were stratified into two groups with CD<1500 mg (Group A) v. CD≥1500 mg (Group B). ROC curve analysis was performed to determine the 1500 mg cut-off value. Overall survival (OS) was estimated using Kaplan-Meier method.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berardi R, Torniai M, Onofri A, Partelli S, Guglielmi S,

Keywords: pancreatic neuroendocrine tumor, targeted therapy, mTOR inhibitors, everolimus, cumulative dose ,